Medicina de precisión, algo está cambiando en la reumatología

Francisco J. Blanco-García

doi:10.7399/fh.11584

Medicina de precisión, algo está cambiando en la reumatología

Francisco J. Blanco-García

Resumen

Texto completo:

PDF (English) PDF

Referencias

Pitzalis C, Choy EHS, Buch MH. Transforming clinical trials in rheumatology: towards patient-centric precision medicine. Nat Rev Rheumatol. 2020;16(10):590-9. DOI: 10.1038/s41584-020-0491-4

Blanco FJ, Ruiz-Romero C. Osteoarthritis: Metabolomic characterization of metabolic phenotypes in OA. Nat Rev Rheumatol. 2012;8:130-2.

Ramudo-Cela L, López-Martí JM, Colmeiro-Echeberría D, de-Uña- Iglesias D, Santomé-Collazo JL, Monserrat-Iglesias L. Desarrollo y validación de un panel de secuenciación masiva en paralelo para farmacogenética clínica. Farm Hosp. 2020;44(6):243-53. DOI: 10.7399/fh.11353

Barbarino JM, Kroetz DL, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for human leukocyte antigen B. [Internet]. Pharmacogenet Genomics. 2015;25(4):205-21 [accessed 15/10/2020]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25647431

Smolen J, Landewé R, Bijlsma J, Burmester G, Chalzidionysion K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77. DOI:10.1136/annrheumdis-2016-210715

Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis. 2011;70:2063-70.

Karsdal MA, Bay-Jensen AC, Henriksen K, Christiansen C, Genant HK, Chamberlain Ch, et al. Rheumatoid arthritis: a case for personalized health care? Arthritis Care Res (Hoboken). 2014;66:1273-80.

Tarnowski M, Paradowska-Gorycka A, Dabrowska-Zamojcin E, Czerewaty M, Sluczanowska-Glabowska S, Pawlik A. The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opin Drug Metab Toxicol. 2016;12:41-55.

Ruiz-Romero C, Rego-Pérez I, Blanco FJ. What did we learn from ‘omics’ studies in osteoarthritis. Curr Opin Rheumatol. 2018;30(1):114- 20.

Courvoisier DS, Chatzidionysiou K, Mongin D, Lauper K, Mariette X, Morel J, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 2020. Available at: https://doi.org/10.1093/rheumatology/keaa393

Lourido L, Ruiz-Romero C, Picchi F, Diz-Rosales N, Vilaboa-Galán S, Fernández-López C, et al. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study. Semin Arthritis Rheum. 2020;50(5):1101- 8.

Blanco FJ, Camacho-Encina M, González-Rodríguez L, Rego-Pérez I, Mateos J, Fernández-Puente P, et al. Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis. Ther Adv Chronic Dis. 2019. DOI: 10.1177/2040622319870013

DOI: http://dx.doi.org/10.7399%2Ffh.11584